Lynn Riley

TORONTO, ONTARIO, April 28, 2025 – NeuPath Health Inc. (TSXV:NPTH), (“NeuPath” or the “Company”), owner and operator of a network of clinics delivering category-leading chronic pain treatment, today announced that Joseph Walewicz, CEO, will present and participate in one-on-one meetings at the 2025 Bloom Burton & Co. Healthcare Investor Conference to be held May 5 and 6, 2025 at the Metro Toronto Convention Centre.
 
NeuPath Presentation

Date:         Tuesday, May 6, 2025
Time:        11:00 a.m. ET
Format:     30-minute live virtual presentation, including Q&A
Webcast: https://event.summitcast.com/view/hG2KhRan38C8o5wZiWyxNK/exp7o3V4T8r8yWrCfFUdeh

Webcast and replay information for this event will also be available on the Investor Information section of NeuPath’s website at: neupath.com/investors/decks-presentations. A replay of the webcast will remain available for 90 days following the presentation.

About the Conference

The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from premier Canadian publicly traded and private companies through presentations and private meetings. For more information, please visit: bloomburton.com/conference.

About NeuPath

NeuPath operates a network of healthcare clinics and related businesses focused on improved access to care and outcomes for patients by leveraging best-in-class treatments and delivering patient-centered multidisciplinary care. We operate a network of medical clinics in Ontario and Alberta that provide comprehensive assessments and rehabilitation services to clients with chronic pain, musculoskeletal/back injuries, sports related injuries and concussions. In addition, NeuPath provides workplace health services and independent medical assessments to employers and disability insurers through a national network of healthcare providers, as well as contract research services to pharmaceutical and biotechnology companies. NeuPath is focused on enabling each individual to live their best life. For additional information, please visit www.neupath.com.

Forward-Looking Statements

This news release contains forward-looking statements. All statements, other than statements of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future. These forward-looking statements reflect the current expectations or beliefs of the Company based on information currently available to the Company. Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, the Company. Factors that could cause actual results or events to differ materially from current expectations included in this news release include, among other things, adverse market conditions, risks associated with obtaining and maintaining the necessary governmental permits and licenses related to the business of the Company, increasing competition in the market and other risks generally inherent in the chronic pain, sports medicine, concussion and workplace health services markets. A comprehensive discussion of these and other risks and uncertainties can be found in the Company’s Annual Information Form dated March 26, 2025 filed on SEDAR+ under the Company’s profile at www.sedarplus.ca. 

Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Although the Company believes that the assumptions underlying the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to their inherent uncertainty.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS THE RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

For more information, please contact:

Jeff Zygouras
Chief Financial Officer
[email protected]
(905) 858-1368

• New role strengthens executive team’s ability to leverage operational turnaround, improved cash flow and recently secured credit facility to accelerate growth
• Mr. Lemieux’s financial expertise, M&A experience and knowledge of NeuPath operations will enable him to contribute effectively from the outset

TORONTO, ONTARIO, April 15, 2025 – NeuPath Health Inc. (TSXV:NPTH), (“NeuPath” or the “Company”), owner and operator of a network of clinics delivering category-leading chronic pain treatment, is pleased to announce the appointment of Stephen Lemieux, CPA, in the newly created role of President, effective May 1, 2025. Mr. Lemieux brings more than 20 years of executive experience in the healthcare and biopharmaceutical sectors, with a successful track record in operations, financial strategy and M&A execution.

Reporting to the CEO, as President, Mr. Lemieux will lead the implementation of NeuPath’s strategy to accelerate inorganic and organic growth and optimize operating margins. This is expected to involve broadened service offerings, new locations, and acquisitions of existing clinics and their teams. He will also lead the exploration of adjacent markets for opportunities that capitalize on the Company’s brand, real estate footprint and operational capabilities. His hiring is the next step in the Company’s growth plan, building on the Company’s successful financial and operational turnaround and newly secured credit facilities to drive accretive growth.

“We are thrilled to welcome Stephen back to NeuPath in this new leadership role,” said Joe Walewicz, CEO of NeuPath. “His operational and financial background are ideally suited to help unlock the full potential of our platform. His familiarity with our people and operations will allow him to hit the ground running. With our strengthened executive team, we’re well-equipped to implement the next phase of our growth plan.”

“I am excited to rejoin NeuPath and lead the organization into its next phase of growth,” added Mr. Lemieux. “The Company has made great progress in recent quarters, and I look forward to working with our talented team to continue improving performance, executing on our strategic plan and expanding our footprint to better serve patients across Canada.”

Mr. Lemieux previously served as the Company’s Chief Financial Officer and Corporate Secretary from 2019 to 2021, when he spearheaded NeuPath’s successful expansion into Alberta. Prior to rejoining NeuPath, he served as CFO at Edesa Biotech (Nasdaq:EDSA) and held senior leadership roles at Cipher Pharmaceuticals (TSX:CPH) and Nuvo Pharmaceuticals (now part of Apotex), among others. Mr. Lemieux is a Chartered Professional Accountant and holds a Master of Management & Professional Accounting degree from the University of Toronto.

His appointment underscores NeuPath’s commitment to building the right leadership team to drive shareholder value through operational excellence and growth.

About NeuPath

NeuPath operates a network of healthcare clinics and related businesses focused on improved access to care and outcomes for patients by leveraging best-in-class treatments and delivering patient-centered multidisciplinary care. We operate a network of medical clinics in Ontario and Alberta that provide comprehensive assessments and rehabilitation services to clients with chronic pain, musculoskeletal/back injuries, sports related injuries and concussions. In addition, NeuPath provides workplace health services and independent medical assessments to employers and disability insurers through a national network of healthcare providers, as well as contract research services to pharmaceutical and biotechnology companies. NeuPath is focused on enabling each individual to live their best life. For additional information, please visit www.neupath.com.

Forward-Looking Statements

This news release contains forward-looking statements. All statements, other than statements of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future including, without limitation, effective date of Mr. Lemieux’s appointment. These forward-looking statements reflect the current expectations or beliefs of the Company based on information currently available to the Company. Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, the Company. Factors that could cause actual results or events to differ materially from current expectations included in this news release include, among other things, adverse market conditions, risks associated with obtaining and maintaining the necessary governmental permits and licenses related to the business of the Company, increasing competition in the market and other risks generally inherent in the chronic pain, sports medicine, concussion and workplace health services markets. A comprehensive discussion of these and other risks and uncertainties can be found in the Company’s annual information form dated March 26, 2025 filed on SEDAR+ under the Company’s profile at www.sedarplus.ca.

Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Although the Company believes that the assumptions underlying the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to their inherent uncertainty.

For more information, please contact:

Jeff Zygouras
Chief Financial Officer
[email protected]
(905) 858-1368

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS THE RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

• Delivered record quarterly total revenues of $15.9 million and record quarterly non-clinic revenues of $1.0 million in the second quarter of 2022
• Adjusted EBITDA⁽¹⁾ was in line with the comparative three-month period, and increased by 140% quarter-over-quarter to $0.8 million
• 14^th consecutive quarter of positive adjusted EBITDA
• Delivered growth with the opening of two new fluoroscopy suites in July 2022, with two more fluoroscopy suites scheduled to be opened in Fall 2022
• Remains committed to accelerated growth strategy

TORONTO, ONTARIO, August 18, 2022 – NeuPath Health Inc. (TSXV:NPTH), (“NeuPath” or the “Company”), owner and operator of a network of clinics delivering category-leading chronic pain treatment, today announced its financial and operating results for the three and six months ended June 30, 2022. All figures are in Canadian dollars, unless otherwise noted.

Financial and Operational Highlights

• Record quarterly revenue of $15.9 million and record quarterly non-clinic revenue of $1.0 million for the three months ended June 30, 2022, compared to $15.9 million and $0.7 million for the comparative three-month period;
• For the six months ended June 30, 2022, revenue grew by 4% to $31.3 million compared to $30.1 million for the comparative six-month period;
• Adjusted EBITDA was $0.8 million and $1.1 million for the three and six months ended June 30, 2022 compared to $0.8 million and $1.8 million for the comparative three and six-month periods;
• Adjusted EBITDA for the three months ended June 30, 2022 increased by $0.5 million or 140% quarter-over-quarter;
• Opened two new fluoroscopy suites in July 2022, with two more fluoroscopy suites scheduled to be opened in Fall 2022, enabling the Company to better serve our patients and expand our service offerings.
• Conducted a strategic review that identified several opportunities for business improvements and began implementation of an accelerated growth strategy, which included several changes at the senior leadership level.

“NeuPath made a great deal of progress towards building a platform for future growth with the recent opening of two new fluoroscopy suites and the first patient visits to our new HealthPointe At CAO clinic in Red Deer,” stated Dianne Carmichael, NeuPath’s Executive Chair. “We expect further business improvements as our recent infrastructure investments allow us to better serve and reach more patients. Further, we continue to evaluate new opportunities to expand our service offering and expand our footprint across Canada.”

View entire press release – PDF